Discovering the potential of targetted therapeutics. Dr Davidson Ateh, CEO, BioMoti




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Discovering the potential of targetted therapeutics. Dr Davidson Ateh, CEO, BioMoti
Released on: June 25, 2015. © PTV
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Dr Davidson Ateh, CEO, BioMoti
  • Summary
  • Transcript
  • Participants
  • Company
Dr Davidson Ateh, CEO, BioMoti
One in three of us will get cancer and increases in life expectancy indices will exacerbate this statistic in the future. Most current treatment options are poorly effective and have devastating side effects including hair loss, nausea, weakened immunity and fatigue to name but a few. However, advances in genomics, epigenomics and proteomics are informing a new era of milder and more effective treatments. This includes targeted therapies, immunotherapies, nanomedicines and patient biomarker stratification strategies making this the most exciting era to be working in cancer drug development. BioMoti exists to transform the treatment of cancer patients by doing things differently. Oncojans™ are a new class of immunotherapeutic drug-loaded particles that target and gain entry to the tumour vasculature and cancer cells. They do this by taking advantage of the CD95L surface ligand that is selectively and heavily expressed in tumour vasculature and cancer cells but not healthy tissue. CD95L promotes tumour immune evasion, cancer cell proliferation and metastasis. It is an essential gene for cancer survival and promotes cancer stem cells. High levels of CD95L expression in patient tumours are associated with increased malignancy and poor prognosis. Once inside CD95L+ve tumour cells, Oncojans™ slowly release therapeutic drugs at the point of need whilst sparing healthy tissue. The oncojan™ platform is compatible with a range of drug classes from small molecule therapeutics to larger biologicals.
One in three of us will get cancer and increases in life expectancy indices will exacerbate this statistic in the future. Most current treatment options are poorly effective and have devastating side effects including hair loss, nausea, weakened immunity and fatigue to name but a few. However, advances in genomics, epigenomics and proteomics are informing a new era of milder and more effective treatments. This includes targeted therapies, immunotherapies, nanomedicines and patient biomarker stratification strategies making this the most exciting era to be working in cancer drug development. BioMoti exists to transform the treatment of cancer patients by doing things differently. Oncojans™ are a new class of immunotherapeutic drug-loaded particles that target and gain entry to the tumour vasculature and cancer cells. They do this by taking advantage of the CD95L surface ligand that is selectively and heavily expressed in tumour vasculature and cancer cells but not healthy tissue. CD95L promotes tumour immune evasion, cancer cell proliferation and metastasis. It is an essential gene for cancer survival and promotes cancer stem cells. High levels of CD95L expression in patient tumours are associated with increased malignancy and poor prognosis. Once inside CD95L+ve tumour cells, Oncojans™ slowly release therapeutic drugs at the point of need whilst sparing healthy tissue. The oncojan™ platform is compatible with a range of drug classes from small molecule therapeutics to larger biologicals.
One in three of us will get cancer and increases in life expectancy indices will exacerbate this statistic in the future. Most current treatment options are poorly effective and have devastating side effects including hair loss, nausea, weakened immunity and fatigue to name but a few. However, advances in genomics, epigenomics and proteomics are informing a new era of milder and more effective treatments. This includes targeted therapies, immunotherapies, nanomedicines and patient biomarker stratification strategies making this the most exciting era to be working in cancer drug development. BioMoti exists to transform the treatment of cancer patients by doing things differently. Oncojans™ are a new class of immunotherapeutic drug-loaded particles that target and gain entry to the tumour vasculature and cancer cells. They do this by taking advantage of the CD95L surface ligand that is selectively and heavily expressed in tumour vasculature and cancer cells but not healthy tissue. CD95L promotes tumour immune evasion, cancer cell proliferation and metastasis. It is an essential gene for cancer survival and promotes cancer stem cells. High levels of CD95L expression in patient tumours are associated with increased malignancy and poor prognosis. Once inside CD95L+ve tumour cells, Oncojans™ slowly release therapeutic drugs at the point of need whilst sparing healthy tissue. The oncojan™ platform is compatible with a range of drug classes from small molecule therapeutics to larger biologicals.